Screening for Placental Dysfunction Before Clinical Signs: Evidence, Mechanisms, and Clinical Practice

Abstract

Placental dysfunction is a pivotal cause of adverse pregnancy outcomes, including preeclampsia, fetal growth restriction, and stillbirth. Early screening for placental dysfunction prior to the onset of clinical symptoms offers a window of opportunity for risk stratification and intervention. This comprehensive review synthesizes the current evidence on screening modalities, underlying mechanisms, risk factors, and evolving strategies for early detection of placental dysfunction. Clinical and scientific insights are provided, highlighting the impact of timely diagnosis and the integration of novel biomarkers and imaging technologies within contemporary guidelines.

Introduction

The placenta is central to fetal development, serving as the interface for nutrient and gas exchange between mother and fetus. Placental dysfunction encompasses a spectrum of pathological processes that compromise placental structure and function, often preceding clinical manifestations such as hypertension, proteinuria, or fetal growth abnormalities. Given the grave implications for maternal and perinatal health, the early identification of placental dysfunction represents a priority in obstetric care. This review aims to elucidate the rationale, evidence, and practicalities of screening for placental dysfunction before clinical signs become apparent.

Epidemiology / Disease Burden

Placental dysfunction is implicated in up to 8% of all pregnancies and is the principal underlying factor in preeclampsia (affecting 2–8% of pregnancies), fetal growth restriction (FGR), and a significant proportion of stillbirths. The burden is particularly high in low-resource settings, where access to prenatal surveillance may be limited. Maternal morbidity, perinatal mortality, and long-term sequelae such as neurodevelopmental impairment and metabolic syndrome in offspring underscore the need for effective screening strategies. Epidemiological studies consistently demonstrate that early placental pathology often precedes overt clinical symptoms by weeks or months, supporting the rationale for preclinical detection.

Pathophysiology

Placental dysfunction arises from abnormal trophoblastic invasion, impaired spiral artery remodeling, and inadequate placental perfusion. This leads to hypoxia, oxidative stress, and the release of anti-angiogenic factors such as soluble fms-like tyrosine kinase-1 (sFlt-1), which antagonizes vascular endothelial growth factor (VEGF). The resultant endothelial dysfunction underpins the development of maternal hypertension and proteinuria seen in preeclampsia, and contributes to the restricted nutrient and oxygen delivery characteristic of FGR. Mechanistically, these processes begin early in gestation, often before clinical recognition, highlighting the pathobiological basis for antecedent screening.

Risk Factors

Numerous maternal, fetal, and placental factors elevate the risk of placental dysfunction. Major risk factors include a history of preeclampsia or FGR, chronic hypertension, diabetes mellitus, renal disease, autoimmune conditions (e.g., antiphospholipid syndrome), multiple gestation, advanced maternal age, and obesity. Assisted reproductive technologies and certain ethnic backgrounds also confer higher risk. The presence of these risk factors justifies intensified surveillance and consideration of early screening modalities in identified individuals.

Clinical Features

Clinical manifestations of placental dysfunction such as hypertension, proteinuria, fetal growth restriction, and oligohydramnios typically emerge in the second or third trimester. However, subclinical placental pathology may be present much earlier, detectable only through specialized testing. The silent nature of early placental dysfunction underpins the need for proactive screening to initiate timely interventions and mitigate adverse outcomes.

Diagnosis

Traditional diagnosis relies on the appearance of clinical signs, but advances in screening incorporate a multimodal approach. Key tools include first-trimester uterine artery Doppler velocimetry to assess placental perfusion, serum biomarkers such as placental growth factor (PlGF) and sFlt-1, and comprehensive risk scoring algorithms. Integration of maternal characteristics, biophysical markers, and biochemical indices enhances predictive accuracy. The Fetal Medicine Foundation algorithm and the ASPRE trial protocol exemplify evidence-based screening strategies that combine these modalities to identify women at risk before symptoms arise.

Treatment & Management

Once placental dysfunction is identified preclinically, management focuses on risk modification and close monitoring. Low-dose aspirin initiated before 16 weeks gestation in high-risk women has demonstrated efficacy in reducing the incidence of preeclampsia and FGR. Serial ultrasonography to monitor fetal growth, Doppler studies, and maternal blood pressure surveillance are standard. Multidisciplinary management involving obstetricians, maternal-fetal medicine specialists, and neonatologists is critical for optimizing outcomes. Early referral to tertiary care and individualized delivery planning may be warranted in severe cases.

Recent Advances / Emerging Therapies

Recent research has explored novel biomarkers, such as cell-free fetal DNA and microRNAs, for earlier and more precise detection of placental dysfunction. Advanced imaging modalities, including three-dimensional power Doppler and placental MRI, offer enhanced visualization of placental structure and function. Artificial intelligence and machine learning approaches are being developed to refine risk prediction and integrate complex datasets. Clinical trials are ongoing to assess the efficacy of additional pharmacologic agents, such as statins and antioxidants, for placental protection in high-risk pregnancies.

Guideline Recommendations

Major obstetric societies, including the American College of Obstetricians and Gynecologists (ACOG) and the International Federation of Gynecology and Obstetrics (FIGO), recommend first-trimester screening for preeclampsia in high-risk women using a combination of maternal factors, biophysical markers, and biochemical tests. Aspirin prophylaxis is endorsed for women identified at increased risk. Guidelines emphasize the importance of individualized risk assessment, the use of validated screening tools, and the timely initiation of preventive strategies. Continued research and guideline refinement are anticipated as new evidence emerges.

Conclusion

Screening for placental dysfunction before the onset of clinical signs is a transformative strategy in modern obstetrics, offering the potential to reduce serious maternal and perinatal complications. Advances in biomarker discovery, imaging, and predictive modeling have enhanced our ability to identify at-risk pregnancies early, enabling tailored intervention and surveillance. Ongoing research and guideline evolution will further optimize screening protocols, with the ultimate goal of improving outcomes for mothers and their infants.